Johnson & Johnson (JNJ) Return on Invested Capital (ROIC): 13.71%
Is Johnson & Johnson’s return on invested capital (ROIC) high or low?
Johnson & Johnson's return on invested capital (ROIC) of 13.71% is in line with its 5-year average of 13.87%, around the middle of its 5-year range (12.31%–16.61%).
As of Thursday, June 11, 2026. 0.15% below its 12-month average of 13.73%.
JNJ Return on Invested Capital (ROIC) Chart
JNJ Average Return on Invested Capital (ROIC) Chart
JNJ Current vs Average Return on Invested Capital (ROIC) Chart
JNJ Return on Invested Capital (ROIC) Metrics
RETURN ON INVESTED CAPITAL (ROIC)
13.71%
RETURN ON INVESTED CAPITAL (ROIC) AVG TTM
13.73%
RETURN ON INVESTED CAPITAL (ROIC) AVG 3Y
14.10%
RETURN ON INVESTED CAPITAL (ROIC) AVG 5Y
13.87%
RETURN ON INVESTED CAPITAL (ROIC) AVG 10Y
12.84%
RETURN ON INVESTED CAPITAL (ROIC) AVG 15Y
13.27%
RETURN ON INVESTED CAPITAL (ROIC) AVG 20Y
14.55%
CURRENT VS TTM AVG
-0.15%
CURRENT VS 3Y AVG
-2.73%
CURRENT VS 5Y AVG
-1.18%
CURRENT VS 10Y AVG
+6.77%
CURRENT VS 15Y AVG
+3.33%
CURRENT VS 20Y AVG
-5.76%
JNJ Competitors' Return on Invested Capital (ROIC)
| NAME | MARKET CAP | RETURN ON INVESTED CAPITAL (ROIC) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Johnson & Johnson (JNJ) | $577.73B | 13.71% | 13.73% | 14.10% | 13.87% |
| Pfizer Inc. (PFE) | $149.61B | 8.84% | 9.06% | 10.60% | 10.43% |
| Merck & Co., Inc. (MRK) | $298.23B | 18.27% | 18.62% | 14.12% | 12.73% |
| AbbVie Inc. (ABBV) | $399.86B | 12.97% | 10.91% | 11.35% | 11.16% |
| Eli Lilly and Company (LLY) | $1.10T | 30.20% | 28.28% | 24.95% | 23.04% |
| Bristol-Myers Squibb Company (BMY) | $116.13B | 13.90% | 13.75% | 11.92% | 10.17% |
Capital Efficiency
ROIC
13.7%
ROE
25.9%
Johnson & Johnson Return on Invested Capital (ROIC) Formula & Definition
ROIC = NOPAT / Invested Capital
Return on invested capital measures the after-tax return a company earns on all capital (debt and equity) invested in the business.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Johnson & Johnson Return on Invested Capital (ROIC) FAQ
- What is the return on invested capital (ROIC) for Johnson & Johnson (JNJ)?
- The return on invested capital (ROIC) for JNJ stock is 13.71%.
- Is Johnson & Johnson's return on invested capital (ROIC) high or low?
- Johnson & Johnson's return on invested capital (ROIC) of 13.71% is in line with its 5-year average of 13.87%, around the middle of its 5-year range (12.31%–16.61%).
- What is the TTM average return on invested capital (ROIC) for Johnson & Johnson (JNJ)?
- The TTM average return on invested capital (ROIC) for JNJ stock is 13.73%.
- What is the 3Y average return on invested capital (ROIC) for Johnson & Johnson (JNJ)?
- The 3Y average return on invested capital (ROIC) for JNJ stock is 14.10%.
- What is the 5Y average return on invested capital (ROIC) for Johnson & Johnson (JNJ)?
- The 5Y average return on invested capital (ROIC) for JNJ stock is 13.87%.
- What is the 10Y average return on invested capital (ROIC) for Johnson & Johnson (JNJ)?
- The 10Y average return on invested capital (ROIC) for JNJ stock is 12.84%.
- What is the 15Y average return on invested capital (ROIC) for Johnson & Johnson (JNJ)?
- The 15Y average return on invested capital (ROIC) for JNJ stock is 13.27%.
- What is the 20Y average return on invested capital (ROIC) for Johnson & Johnson (JNJ)?
- The 20Y average return on invested capital (ROIC) for JNJ stock is 14.55%.
Johnson & Johnson Return on Invested Capital (ROIC) History
| DATE | RETURN ON INVESTED CAPITAL (ROIC) |
|---|---|
| 2025-12-28 | 13.71% |
| 2024-12-29 | 13.75% |
| 2023-12-31 | 16.61% |
| 2023-01-01 | 12.31% |
| 2022-01-02 | 13.83% |
| 2021-01-03 | 13.03% |
| 2019-12-31 | 14.88% |
| 2018-12-31 | 14.45% |
| 2017-12-31 | 1.06% |
| 2016-12-31 | 14.59% |
| 2015-12-31 | 13.03% |
| 2014-12-31 | 15.30% |
| 2013-12-31 | 15.15% |
| 2012-12-31 | 12.77% |
| 2011-12-31 | 12.96% |
| 2010-12-31 | 14.87% |
| 2009-12-31 | 16.37% |
| 2008-12-31 | 18.24% |
| 2007-12-31 | 19.05% |
| 2006-12-31 | 18.56% |
| 2005-12-31 | 20.99% |
| 2004-12-31 | 20.66% |
| 2003-12-31 | 21.11% |
| 2002-12-31 | 22.01% |
| 2001-12-31 | 18.25% |
| 2000-12-31 | 16.75% |
| 1999-12-31 | 18.51% |
| 1998-12-31 | 16.60% |
| 1997-12-31 | 19.76% |
| 1996-12-31 | 19.62% |
Related Metrics
About Johnson & Johnson
Johnson & Johnson (JNJ) operates globally, engaging in the research, development, production, and distribution of a diverse range of healthcare products. In a pivotal strategic move in 2023, the company divested its Consumer Health division, establishing it as the independent entity Kenvue Inc. This separation was implemented to allow J&J to sharpen its focus on higher-growth, innovation-led areas. Consequently, well-known consumer brands like TYLENOL, LISTERINE, and BAND-AID are now part of Kenvue's portfolio. Johnson & Johnson's current operations are centered around two primary divisions: Innovative Medicine and MedTech. The Innovative Medicine segment, formerly known as Pharmaceuticals, specializes in prescription drugs designed to treat complex ailments such as rheumatoid arthritis, various forms of cancer, HIV/AIDS, and neurodegenerative disorders. Its MedTech division, encompassing Medical Devices, delivers cutting-edge technological solutions, including electrophysiology equipment, neurovascular care products, orthopaedic implants for hips, knees, and spine, advanced surgical technologies, and ACUVUE brand disposable contact lenses. These two streamlined segments primarily cater to a client base comprising hospitals, medical professionals, wholesale distributors, and retail outlets. From its headquarters in New Brunswick, New Jersey, Johnson & Johnson continues to uphold its enduring mission of advancing human health, a commitment it has maintained since its founding in 1886.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Joaquin Duato